scans

Acticor Biotech gets patent for cardiovascular emergency treatment product

French company Acticor Biotech has announced the European Patent Office (EPO) has granted a new patent that provides protection for the use of Acticor’s product, glenzocimab in thrombotic diseases in Europe until 2036.

The grant in Europe complements the ones already obtained in November 2020 in the U.S. and in November 2021 in Singapore, both of which also protect glenzocimab until 2036ell. The patent is also under examination in other countries such as Japan.

To date, three patent families, including four granted patents and 33 pending patent applications, protect glenzocimab and its therapeutic use. read more